Close menu




July 22nd, 2026 | 07:55 CEST

Millions in Losses at Eutelsat! Warning Sparks Panic at Evotec! Can Zefiro Methane Save Your Portfolio?

  • methane
  • OrphanWells
  • Satellites
  • Biotechnology
Photo credits: Pixabay

The geopolitical situation is currently escalating dramatically. The latest news from the Middle East is coming in fast and furious. A massive military exchange between the US and Iran threatens to profoundly shake the global economy. Burning oil refineries in Kuwait, dead soldiers, and wailing sirens in the Gulf state of Bahrain paint a grim picture of the current security situation. Such rapidly escalating crises are driving oil prices sky-high and have the potential to send shockwaves through international financial markets. In these particularly turbulent times, many investors are desperately seeking safe havens. While once-coveted AI and tech stocks, as well as biotech hopefuls, are collapsing under the weight of global uncertainty and, in some cases, their own internal issues, lucrative niche markets are increasingly coming into focus. Today, we take a look at three different stocks. First, we examine the severe setback at Evotec, the costly strategic hurdles at Eutelsat, and the astonishing resilience of Zefiro Methane.

time to read: 4 minutes | Author: Matthias Schomber
ISIN: ZEFIRO METHANE CORP | CA98926D1069 | NEO: ZEFI , EUTELSAT COMMS EO 1 | FR0010221234 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    Author

    Matthias Schomber

    Matthias Schomber

    Raised in Giessen, Hesse, Matthias Schomber discovered his passion for the financial markets as early as the 1990s—at a time when stock trading was still largely the domain of true, die-hard traders. After completing his banking apprenticeship, he worked for a private bank there and witnessed the rise and fall of the Neuer Markt firsthand on the trading floor of the Frankfurt Stock Exchange, drawing lessons from the experience that continue to shape his thinking as a trader, author, and trading system developer to this day.

    About the author



    Tag cloud


    Shares cloud

    Evotec: In Free Fall Toward a Ten-Year Low

    We begin our analysis with a real problem child. The stock of the Hamburg-based biotech company Evotec has experienced an almost unprecedented bloodbath in recent weeks. Following a drastic profit warning and a sharp downward revision of its annual forecast, the stock headed in only one direction. The share price has literally plummeted and is currently trading just above its most recent ten-year low of EUR 3.17 at around EUR 3.55. Virtually nothing remains of the stock's former highs—five years ago, it was still trading above EUR 45.

    Analysts are now also pulling the plug one after another and drastically lowering their price targets. The ongoing delay of key milestone payments and severe operating losses have deeply shaken investor confidence. From a technical analysis perspective, the stock is in a massive downtrend. A viable support zone has yet to be painstakingly identified. There is pure uncertainty in the market. Anyone hoping for a quick recovery here is currently playing with fire. There is, however, a glimmer of hope. The RSI stands at 27 points, and in the past, the stock has often rebounded from that level. In any case, as the saying goes, hope dies last.

    Eutelsat: Between Heavy Losses and High Hopes

    From the depths of the biotechnology sector surrounding Evotec, we now turn our attention to space. While the situation there is different, it is by no means worry-free. In the satellite business, too, the major players are grappling with enormous financial burdens and extremely fierce competition. The French company Eutelsat is currently at the center of a heated debate. The British government, in particular, is likely to be swallowing hard as it looks at its portfolio, as the government's stake in OneWeb has now resulted in a massive book loss of around 340 million British pounds.

    Eutelsat's share price clearly reflects this investor skepticism. Trading at around EUR 2.12, the share is down more than 50% from its 52-week high of EUR 4.56. That high was likely driven in part by the hype surrounding SpaceX's recent IPO. However, since Elon Musk's space stock has recently been on a downward trend and has even fallen below its IPO price, Eutelsat was likely unable to escape this downward pull. The key 200-day moving average has already been broken significantly to the downside. Yet there are certainly bright spots in the company's operations. Revenue in the connectivity segment rose by a strong 65% year-over-year. The strategic shift toward low Earth orbit (LEO) capacity seems to be bearing fruit, at least initially. Nevertheless, operational pressure from aggressive global competitors like Starlink and Amazon remains extremely high. For now, wait for the stock to find a bottom and watch from the sidelines!

    Zefiro Methane: Tangible Solutions for a Billion-Dollar Problem

    While Eutelsat battles for market share high in orbit and Evotec desperately seeks profitability in the lab, we find another company that has identified lucrative solutions in a niche market and is reaping the rewards.

    The Canadian environmental company Zefiro Methane is tackling a mammoth task: professionally sealing decommissioned oil and gas wells that are extremely harmful to the climate. The latest developments look promising across the board.

    A strategic partnership with the renowned Well Done Foundation has secured Zefiro a lucrative contract to plug 10 wells in Oklahoma, with another 20 set to follow in 2027. In addition, the company is benefiting massively from the expansion of new AI data centers: the sites designated for these projects very often contain historical contaminated sites that must be plugged before construction can begin.

    https://youtu.be/nNodjcqNJMM

    A look at the company's financials underscores its enormous potential. Zefiro operates in a market with an estimated total volume of USD 400-600 billion. Over 2.2 million abandoned wells are awaiting closure in the US alone. Zefiro draws on generous government funding and also generates highly sought-after CO2 credits, which have already been successfully sold to companies such as Mercuria Energy and EDF Trading.

    Chart Analysis: Is Zefiro Methane on the Verge of a Technical Breakout?

    The chart pattern for Zefiro shares is particularly exciting right now. Following the dynamic breakout in May above the key CAD 0.60 level and the subsequent high of CAD 0.80, the stock is currently consolidating and trading around the CAD 0.63 level.

    A highly interesting detail is a recent candlestick pattern in the form of a hammer (see chart below). This hammer closed the open gap at exactly CAD 0.52. The market has thus technically completed a downward correction.

    If the stock sustainably rises above the CAD 0.67 level, breaking through the current consolidation line, the breakout should be considered formally successful. After that, a rapid new annual high above CAD 0.80 could be on the horizon, with medium-term potential toward the "magic" CAD 1.00 mark.

    The research firm GBC takes a similar, or even slightly more optimistic, view in its latest analysis of Zefiro Methane. It took a closer look at the company and valued it using a three-stage DCF model. As a result, it has set a price target of CAD 2.12 for the stock. So there is still plenty of room to run!

    There is significant upside potential!

    Following the sharp share price drop, Evotec is left in a shambles and must painstakingly rebuild investor confidence. However, a technical rebound cannot be ruled out due to the stock being heavily oversold. Eutelsat is showing good growth in the LEO segment but is suffering from impairment charges and fierce cutthroat competition from rivals. Zefiro Methane is positioning itself promisingly at the intersection of environmental protection and energy infrastructure. With full order books and a clean technical chart setup, the next upward surge could be just around the corner.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Matthias Schomber

    Matthias Schomber

    Raised in Giessen, Hesse, Matthias Schomber discovered his passion for the financial markets as early as the 1990s—at a time when stock trading was still largely the domain of true, die-hard traders. After completing his banking apprenticeship, he worked for a private bank there and witnessed the rise and fall of the Neuer Markt firsthand on the trading floor of the Frankfurt Stock Exchange, drawing lessons from the experience that continue to shape his thinking as a trader, author, and trading system developer to this day.

    About the author



    Related comments:

    Commented by Lars Winter on October 13th, 2026 | 05:22 CEST

    BioNxt, CrowdStrike and Shell: Three exciting stocks ahead of the next price surge

    • Biotech
    • BioNxt Solutions
    • Crowdstrike
    • Shell
    • Crude Oil
    • Oil
    • Oil Price
    • Commodities
    • Biotechnology
    • Cyber Security
    • Cybersecurity

    On the stock market, facts matter most. New study results, strong figures and solid operational records tend to attract investor attention and often drive share prices higher. These three stocks deserve a closer look: BioNxt Solutions is approaching its first human study, CrowdStrike has reported a record quarter, and Shell is benefiting from exceptionally high refining margins. Three very different stocks, each offering opportunities alongside distinct risks. We take a closer look at these compelling names in our stock check.

    Read

    Commented by Carsten Mainitz on October 12th, 2026 | 05:28 CEST

    Don’t Miss Out! Cancer Research and Comeback Potential: Vidac Pharma, Bayer and Evotec in Focus!

    • Oncology
    • Cancer Therapy
    • Pharma
    • Biotechnology
    • Clinical Trials
    • Innovation

    New cancer therapies are targeting major medical breakthroughs. For investors, however, the key question is when scientific progress will begin to translate into rising share prices. Vidac Pharma is at a particularly exciting stage in its development. The company is awaiting crucial clinical trial data that could validate its innovative approach to cancer cell metabolism and mark a major milestone. Bayer is expanding its oncology business but must also contend with a range of challenges. Meanwhile, Evotec needs to prove it can turn its research, technology platforms, and strategic partnerships into profitable business opportunities while rebuilding lost investor confidence. Which developments could now trigger a revaluation of these three stocks?

    Read

    Commented by André Will-Laudien on October 9th, 2026 | 10:59 CEST

    BioTech Rally 2027: Patents, Blockbusters and Biosimilars! The spotlight is on Bayer, Formycon, Evotec and Novo Nordisk

    • Biotechnology
    • Biotech
    • Pharma
    • biosimilars
    • patents

    The storm in the pharmaceutical sector continues to gain momentum! Expiring patents and struggling healthcare systems are shaking up old, high-margin blockbuster drugs, as societal changes and government budget constraints shake the foundations of costly pharmaceutical development. As patents expire, many generic manufacturers find themselves in a race against time. Market shares are being reshuffled, heralding a new era of growth. Amid this dynamic rally, four well-known industry players are positioning themselves on different fronts to capitalize on the market shifts. After several difficult years, the Leverkusen-based pharmaceutical giant Bayer is fighting its way back with a completely revamped pipeline. Also in the fast lane is the German biosimilar hopeful from Munich, with its first products already on the market. At Hamburg-based drug discovery company Evotec, restructuring is still underway; the key driver is its state-of-the-art, AI-powered multivalent platform. Meanwhile, the Danish giant Novo Nordisk continues to ride the global obesity and diabetes wave, driving forward the next generation of its blockbuster drugs. Analysts do not have it easy, but there are plenty of opportunities for investors.

    Read